Symbol Lookup

Friday July 03, 2015 1:18 PM ET. Data delayed 15 minutes.
12.73
0.17 (1.35%)
Bid/Lots
12.72/1
Ask/Lots
12.73/5
Open/Prev Close
12.63/12.56
Day Range
12.35-12.76
52-Week Range
7.53-17.77
Vol/Avg Daily Vol
154.5K/470.9K

TD Waterhouse offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

CARA Headlines

Go
Cara Therapeutics Completes Enrollment of Phase 2 Trial of I.V. CR845 in Uremic Pruritus
8:00AM ET on Tuesday Jun 23, 2015 by GlobeNewswire
Companies Mentioned: CARA

-- Top-line data expected in early 3Q'15

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced that it has completed enrollment in its Phase 2 proof-of-concept trial of its lead kappa opioid agonist, CR845, for the treatment of uremic pruritus (UP).

-- Top-line data expected in early 3Q'15

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid recepto...

Jun 22, 2015

Why Are Cannabis Labs Important and What Makes Them a Great Investment?
1:16PM ET on Monday Jun 22, 2015 by Accesswire
Companies Mentioned: DIGP, XXII, CARA, MYDX

SEATTLE, WA / ACCESSWIRE / June 22, 2015 / The expansion of the legalized marijuana industry at the state level has created a diverse array of ancillary businesses, each of them with their own competitive landscape and growth potential. This week, GreenWave Advisors, LLC, an independent investment research and advisory firm serving the burgeoning cannabis industry, published a report titled "Marijuana Lab Testing: An in depth analysis of investing in one of the industry's most attractive plays," which projects marijuana lab testing revenues could reach $850 million a year by 2020.

SEATTLE, WA / ACCESSWIRE / June 22, 2015 / The expansion of the legalized marijuana industry at the state level has created a diverse array of ancillary businesses, each of them with their own competitive landscape and growth potential. This we...

Why Are Cannabis Labs Important and What Makes Them a Great Investment?
9:30AM ET on Monday Jun 22, 2015 by Accesswire
Companies Mentioned: XXII, CARA, MYDX

SEATTLE, WA / ACCESSWIRE / June 22, 2015 / The expansion of the legalized marijuana industry at the state level has created a diverse array of ancillary businesses, each of them with their own competitive landscape and growth potential. This week, GreenWave Advisors, LLC, an independent investment research and advisory firm serving the burgeoning cannabis industry, published a report titled "Marijuana Lab Testing: An in depth analysis of investing in one of the industry's most attractive plays," which projects marijuana lab testing revenues could reach $850 million a year by 2020.

SEATTLE, WA / ACCESSWIRE / June 22, 2015 / The expansion of the legalized marijuana industry at the state level has created a diverse array of ancillary businesses, each of them with their own competitive landscape and growth potential. This we...

Jun 10, 2015

Cara Therapeutics to Sponsor Symposium and Present Poster at the College on Problems of Drug Dependence 77th Annual Meeting
8:00AM ET on Wednesday Jun 10, 2015 by GlobeNewswire
Companies Mentioned: CARA

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that it will sponsor a symposium titled "New Analgesic and Abuse Deterrent Approaches: Kappa Opioid Receptor Agonists (KORAs)" at the College on Problems of Drug Dependence (CPDD) 77 Annual Meeting in Phoenix, Arizona. Leading pain experts will discuss the latest developments in analgesia, including data from Cara's Phase 2 trial and human abuse liability study of CR845, the Company's first-in-class peripherally-selective kappa opioid agonist, which has potential to be the only Schedule V or non-scheduled opioid for acute pain.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that it will...

Jun 5, 2015

Cara Therapeutics to Present at the 2015 International Conference on Opioids
8:00AM ET on Friday Jun 05, 2015 by GlobeNewswire
Companies Mentioned: CARA

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Chief Medical Officer Dr. Joseph Stauffer will present data from the Company's human abuse liability study of I.V. CR845 during a poster session at the International Conference on Opioids (ICOO 2015), being held June 7-9 in Boston, MA. CR845 is Cara's first-in-class peripherally-selective kappa opioid receptor agonist, which has potential to be the only Schedule V or non-scheduled opioid for acute pain.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Chief M...

Peers Headlines

Jul 1, 2015

Flex Pharma to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
8:00AM ET on Wednesday Jul 01, 2015 by Business Wire
Companies Mentioned: FLKS

Click to Tweet this News

Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular con...

Dicerna Pharmaceuticals Reports On Employee Stock-Option Plan
7:31AM ET on Wednesday Jul 01, 2015 by Midnight Trader
Companies Mentioned: DRNA
07:31 AM EDT, 07/01/2015 (MT Newswires) -- Dicerna Pharmaceuticals Wednesday reported it granted on June 30 stock options to purchase a total of 115,500 shares of common stock to four new employees. Dicerna, a developer of RNA interference-based ...
Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7:18AM ET on Wednesday Jul 01, 2015 by Business Wire
Companies Mentioned: DRNA

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today ...

Jun 29, 2015

Proteon Therapeutics Announces Addition to Russell 2000 Index
8:00AM ET on Monday Jun 29, 2015 by GlobeNewswire
Companies Mentioned: PRTO

Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that it was added to the Russell 2000(R) index effectiv...

Jun 23, 2015

Synta Pharmaceuticals Confirms Journal Publication Describing Combination of Hsp90 and Immune Checkpoint Blockade for Cancer Therapy; Shares Rise Pre-Market
8:30AM ET on Tuesday Jun 23, 2015 by Midnight Trader
Companies Mentioned: SNTA
08:30 AM EDT, 06/23/2015 (MT Newswires) -- Synta Pharmaceuticals (SNTA) said Tuesday that an in-depth review describing the rationale for pursuing the combination of Hsp90 and immune checkpoint inhibition for cancer therapy appears in this month'...
Synta Announces Journal Publication Describing Complementary Activity of Hsp90 Inhibition and Immune Checkpoint Blockade for Cancer Therapy
8:00AM ET on Tuesday Jun 23, 2015 by Business Wire
Companies Mentioned: SNTA

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the publication in this month's issue of Cancer Immunology Research of an in-depth review describing the rationale for pursuing the combination of Hsp90 and immune ...

Jun 19, 2015

Dicerna to Present at the JMP Securities Life Sciences Conference 2015
11:01AM ET on Friday Jun 19, 2015 by Business Wire
Companies Mentioned: DRNA

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the JMP S...

Jun 17, 2015

Proteon Therapeutics to Present at the JMP Securities Life Science Conference June 24th
8:00AM ET on Wednesday Jun 17, 2015 by GlobeNewswire
Companies Mentioned: PRTO

Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the JMP Securit...

Jun 16, 2015

Synta to Participate in Upcoming Investor Conferences
4:01PM ET on Tuesday Jun 16, 2015 by Business Wire
Companies Mentioned: SNTA

--- Participating in 2nd Annual ROTH Healthcare Corporate Access Day -

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will present at the JMP Securities Life Sciences Conference 2015 on Tuesday,...

Jun 15, 2015

Alfred Sandrock, Jr., M.D., Ph.D., Chief Medical Officer of Biogen, Joins Flex Pharma's Scientific Advisory Board
8:30AM ET on Monday Jun 15, 2015 by Business Wire
Companies Mentioned: BIIB, FLKS

Click to Tweet this News

Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spas...

← Newer12Older →